Table 4.

Scores of SF-36 health survey questionnaire after treatment.

Score	12-week follow-up assessment		24-week follow-up assessment
	Treatment n = 121	Control n = 118	Treatment group n = 112	Control group n = 108
RP	50.39 ± 18.6∗#	52.78 ± 18.02	61.72 ± 20.39∗∗##	52.78 ± 18.02
PF	45.85 ± 14.63∗#	24.29 ± 10.39	48.91 ± 14.95∗∗##	23.89 ± 11.01
GH	46.64 ± 21.34∗#	33.09 ± 621.76	52.66 ± 21.75∗∗##	33.33 ± 22.19
BP	48.91 ± 19.61∗#	36.03 ± 16.32	53.44 ± 20.95∗∗##	41.11 ± 16.86
SF	43.75 ± 10.45∗#	18.25 ± 11.84	57.03 ± 14.41∗∗##	25.19 ± 11.56
VT	58.82 ± 17.54∗#	39.13 ± 19.97	66.09 ± 17.58∗∗##	39.44 ± 21.10
MH	47.56 ± 17.02∗#	40 ± 15.27	53.13 ± 17.79∗∗##	39.87 ± 16.29
RE	51.56 ± 16.72∗#	31.75 ± 24.99	71.35 ± 22.90∗∗##	36.51 ± 25.19

At the 12th week, there were total 121 and 118 patients in treatment group and control group, respectively. At the 24th week, there were total 112 and 108 patients in treatment group and control group, respectively. RP, PF, GH, BP, SF, VT, MH and RE represent for Role-physical, Physical Function, general health, Bodily Pain, Social Function, Vitality, Mental Health, Role-Emotional, respectively. The scores were calculated as $\stackrel{-}{x}\pm s$. *P < 0.05, compared with control group; **P < 0.01, compared with control group. ^# P < 0.05, compared with pretreatment in table1 and ^## P < 0.01 compared with 12th week.